The DNPH1 Knockout A2780 Polyclonal Cells product comprises a heterogeneous population of A2780 human ovarian carcinoma cells engineered via CRISPR/Cas9-mediated gene disruption to permanently inactivate the DNPH1 locus. This polyclonal knockout cell pool retains the diverse clonal representation of the edited population, providing a biologically relevant loss-of-function model for studying DNPH1-dependent processes without the clonal selection biases inherent to monoclonal lines. The knockout strategy introduces targeted genomic alterations that abolish functional DNPH1 protein expression, enabling researchers to assess the cellular consequences of DNPH1 deficiency in a high-grade serous ovarian cancer context.
The parental A2780 cell line is a well-characterized epithelial ovarian carcinoma model established from a treatment-na?ve patient with ovarian endometrioid adenocarcinoma. A2780 cells exhibit pronounced sensitivity to cisplatin and other DNA-damaging agents, making them a valuable system for investigating mechanisms of chemotherapy response and resistance. They harbor wild-type TP53 and retain functional DNA damage response pathways, allowing dissection of how DNPH1 loss intersects with p53-dependent and -independent signaling.
DNPH1 encodes a nucleoside 5′-monophosphate phosphohydrolase that catalyzes the hydrolysis of deoxynucleoside monophosphates (dNMPs) into deoxynucleosides, thereby regulating intracellular dNTP pool sizes. This activity maintains nucleotide homeostasis, prevents aberrant nucleoside incorporation into DNA, and supports DNA repair synthesis. DNPH1 functions at the intersection of the nucleotide salvage pathway and the DNA damage response. Upstream, DNPH1 expression is regulated by genotoxic stress, the tumor suppressor TP53, and the oncogene MYC. Its activity directly influences downstream dNTP pools, DNA replication fidelity, and apoptotic pathways. Knockout disrupts this balance, leading to imbalanced dNTP levels, compromised replication fork progression, and activation of ATM/ATR-mediated DNA damage checkpoints. Related pathway components include ribonucleotide reductase (RRM2) and thymidine kinase 1 (TK1), which coordinate with DNPH1 in dNTP biosynthesis and salvage.
In the A2780 ovarian cancer background, loss of DNPH1 provides a unique model for investigating how dysregulated nucleotide metabolism contributes to genomic instability and tumor cell vulnerability. Because A2780 cells rely on robust DNA repair for survival under genotoxic chemotherapy, DNPH1 knockout may sensitize these cells to cisplatin or other agents by exacerbating replication stress and DNA damage accumulation. This model is particularly suited for studies exploring synthetic lethal relationships, where DNPH1 deficiency could expose dependencies on parallel pathways (such as de novo nucleotide synthesis) or specific DNA repair factors, offering insights into targeted therapeutic strategies for chemotherapy-resistant ovarian cancer.
Researchers can employ these polyclonal DNPH1 knockout A2780 cells in a wide array of functional assays. Western blotting and RNA-sequencing can confirm DNPH1 ablation and assess transcriptional reprogramming; cell proliferation and cell cycle analyses (e.g., propidium iodide staining) reveal growth effects; apoptosis assays (e.g., Annexin V staining) gauge cell death; ??-H2AX immunofluorescence quantifies DNA double-strand breaks; nucleotide pool quantification by HPLC or LC-MS measures dNTP imbalances; cisplatin sensitivity assays and comet assays evaluate genotoxic responses; and phospho-signaling analysis (e.g., phospho-ATM, phospho-p53) dissects checkpoint activation. These applications position the product as a versatile tool for nucleotide metabolism, DNA damage, and drug sensitivity research. For further technical details or to discuss custom applications of this DNPH1 knockout model, please contact Ascent Research.
